Cite
HARVARD Citation
Nitti, V. et al. (2014). Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial. International journal of clinical practice. 68 (8), pp. 972-985. [Online].